Krazati (Adagrasib) Patent Expiration, LOE Window & CMS Spending

Krazati (Adagrasib) by Bristol Myers Squibb: FDA Orange Book core substance LOE 2041-09-10 (last listed 2043-08-21), 0 AB generics, $80.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBristol Myers Squibb
FDA Application & PathwayN216340 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2041-09-10
Last Listed Patent or Exclusivity Date2043-08-21
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$80.7M
2024 Medicare Part D Spend$69.7M
2024 Medicaid Spend$11.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.